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Introduction
Glycogen storage disease, glycogenosis type II (GSDII),
or Pompe disease (OMIM 23230), is an autosomal
recessive lysosomal storage disorder that results from a
deficiency in the acid alpha glucosidase (GAA) enzyme.
The disease is characterized by progressive accumulation
of lysosomal glycogen in various tissues, primarily in
cardiac and skeletal muscles. The histopathological hall-
marks in the muscle are fiber vacuolization and autop-
hagy. GSDII is clinically classified as a severe infantile,
or an attenuated, later-onset form affecting children and
adults. Recombinant human GAA (rhGAA) is the only
approved enzyme replacement therapy (ERT) available
for the treatment of Pompe disease, and it is effective in
infantile patients, whereas in adults, improvements are
more variable among different patients. Our project
aims to assess the effects of ERT in 19 late-onset
patients using both biochemical and morphological (his-
tological, histochemical, and immunohistochemical) eva-
luations of skeletal muscle biopsies before and after
6 months to 1 year on ERT.
Methods
Using baseline and post-ERT muscle biopsy tissue, we
monitored autophagy by immunohistochemical analysis
of the following proteins belonging to vesicular pathways:
EEA1 early endosome, LC3 autophagosomal marker, and
LAMP-2 lysosomal marker. Quantitative evaluations of
fiber diameter, CSA, the number of vacuolated fibers, the
degree of glycogen accumulation, and the percentage of
vacuolization in type I and type II fibers were also
performed.
Results
All patients clinically improved after ERT. Pre-treatment
muscle biopsies showed a histopathologically divergent
spectrum, ranging from almost normal morphology with
very few scattered vacuoles, to severe vacuolar myopa-
thy. Post-treatment muscle biopsies morphologically
improved in two patients, whereas no significant histo-
pathological modifications were seen in all the other
subjects. Immunohistochemical analysis of the autopha-
fagic pathways was very complex and showed variable
binding of the three antibodies in both the first and the
second biopsies.
Conclusion
This study highlights the effectiveness of ERT in
patients with adult onset GSDII and helps shed light on
the role of autophagy in the pathogenesis of the disease.
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